Home > Current

Patent Analysis of Osimertinib in China

Wei-Xing Chen （ Patent Examination Cooperation (Beijing) Center of the Patent Ofice, CNIPA, Beijing, 100070, China ）

https://doi.org/10.37155/2717-5278-0701-2

Abstract

Abstract: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), used in the treatment of non-small cell lung cancer (NSCLC) patients harboring the EGFR T790M mutation. This paper conducts a comprehensive analysis of invention patents related to osimertinib in China. It includes statistics and evaluations on applicant rankings, applicant countries, application-publication trends, technical distribution, and authorization rates. Furthermore, a focused analysis is carried out on AstraZeneca’s key patent portfolio in China. This study aims to provide insight into the technological development trends, hotspots, and focal points in this feld, ofering valuable reference for pharmaceutical enterprises engaging in related R&D.

Keywords

Osimertinib; Non-small cell lung cancer; Lung cancer; Patent

Full Text

PDF

References

[1]U.S. Food and Drug Administration. FDAapproves new pill to treat certain patients with non-small cell lung cancer [EB/OL]. [2015-11-13].Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm.
[2]Remon J, Planchard D.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients. Future Oncol. 2015;11(22):3069–3081.
[3]He Ruilian, Zhang Guoji, He Wenjie. Observation on the Short- and Long-Term Efcacy of Osimertinib in Targeted Therapy for NSCLC. Journal of Practical Oncology, 2021, 36(3): 486–489.
[4]Li Ping, Wang Li, Jia Lechuan. Research Progress on the Third-Generation Epidermal Growth Factor Receptor Inhibitor—Osimertinib. Chinese Journal of Clinical Pharmacology, 2017, 33(14): 1371–1373.

Copyright © 2025 Wei-Xing Chen Creative Commons License Publishing time:2025-02-28
This work is licensed under a Creative Commons Attribution 4.0 International License